198 related articles for article (PubMed ID: 21815268)
1. A heterodimeric glucuronide prodrug for cancer tritherapy: the double role of the chemical amplifier.
Grinda M; Clarhaut J; Tranoy-Opalinski I; Renoux B; Monvoisin A; Cronier L; Papot S
ChemMedChem; 2011 Dec; 6(12):2137-41. PubMed ID: 21815268
[No Abstract] [Full Text] [Related]
2. A new cyclopamine glucuronide prodrug with improved kinetics of drug release.
Renoux B; Legigan T; Bensalma S; Chadéneau C; Muller JM; Papot S
Org Biomol Chem; 2011 Dec; 9(24):8459-64. PubMed ID: 22042246
[TBL] [Abstract][Full Text] [Related]
3. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy.
Legigan T; Clarhaut J; Renoux B; Tranoy-Opalinski I; Monvoisin A; Jayle C; Alsarraf J; Thomas M; Papot S
Eur J Med Chem; 2013 Sep; 67():75-80. PubMed ID: 23845743
[TBL] [Abstract][Full Text] [Related]
5. Extended scaffold glucuronides: en route to the universal synthesis of O-aryl glucuronide prodrugs.
Walther R; Jarlstad Olesen MT; Zelikin AN
Org Biomol Chem; 2019 Jul; 17(29):6970-6974. PubMed ID: 31290904
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation.
Prijovich ZM; Burnouf PA; Chou HC; Huang PT; Chen KC; Cheng TL; Leu YL; Roffler SR
Mol Pharm; 2016 Apr; 13(4):1242-50. PubMed ID: 26824303
[TBL] [Abstract][Full Text] [Related]
7. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.
Chen KC; Schmuck K; Tietze LF; Roffler SR
Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264
[TBL] [Abstract][Full Text] [Related]
8. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
[TBL] [Abstract][Full Text] [Related]
9. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy.
Leu YL; Chen CS; Wu YJ; Chern JW
J Med Chem; 2008 Mar; 51(6):1740-6. PubMed ID: 18318465
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin.
Legigan T; Clarhaut J; Renoux B; Tranoy-Opalinski I; Monvoisin A; Berjeaud JM; Guilhot F; Papot S
J Med Chem; 2012 May; 55(9):4516-20. PubMed ID: 22515366
[TBL] [Abstract][Full Text] [Related]
11. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
[TBL] [Abstract][Full Text] [Related]
12. Preparation of a camptothecin prodrug with glutathione-responsive disulfide linker for anticancer drug delivery.
Xu Z; Wang D; Xu S; Liu X; Zhang X; Zhang H
Chem Asian J; 2014 Jan; 9(1):199-205. PubMed ID: 24136878
[TBL] [Abstract][Full Text] [Related]
13. A prodrug nanoassembly entrapping drugs as a tumor-targeted delivery system.
Yuan Z; Yi X; Zhang J; Cheng S; Zhuo R; Li F
Chem Commun (Camb); 2013 Jan; 49(8):801-3. PubMed ID: 23235958
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and characterization of a photoresponsive doxorubicin/combretastatin A4 hybrid prodrug.
Liu W; Liang L; Zhao L; Tan H; Wu J; Qin Q; Gou X; Sun X
Bioorg Med Chem Lett; 2019 Feb; 29(3):487-490. PubMed ID: 30553736
[TBL] [Abstract][Full Text] [Related]
15. In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.
Radi M; Adema AD; Daft JR; Cho JH; Hoebe EK; Alexander LE; Peters GJ; Chu CK
J Med Chem; 2007 May; 50(9):2249-53. PubMed ID: 17419604
[TBL] [Abstract][Full Text] [Related]
16. Duocarmycin-based prodrugs for cancer prodrug monotherapy.
Tietze LF; Schuster HJ; Schmuck K; Schuberth I; Alves F
Bioorg Med Chem; 2008 Jun; 16(12):6312-8. PubMed ID: 18524605
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia activated prodrugs of a 9-aza-anthrapyrazole derivative that has promising anticancer activity.
El-Dakdouki MH; Adamski N; Foster L; Hacker MP; Erhardt PW
J Med Chem; 2011 Dec; 54(23):8224-7. PubMed ID: 22011244
[TBL] [Abstract][Full Text] [Related]
18. Cell-specific, activatable, and theranostic prodrug for dual-targeted cancer imaging and therapy.
Santra S; Kaittanis C; Santiesteban OJ; Perez JM
J Am Chem Soc; 2011 Oct; 133(41):16680-8. PubMed ID: 21910482
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard.
Lougerstay-Madec R; Florent JC; Monneret C; Nemati F; Poupon MF
Anticancer Drug Des; 1998 Dec; 13(8):995-1007. PubMed ID: 10335272
[TBL] [Abstract][Full Text] [Related]
20. A macromolecular prodrug strategy for combinatorial drug delivery.
Li NN; Lin J; Gao D; Zhang LM
J Colloid Interface Sci; 2014 Mar; 417():301-9. PubMed ID: 24407691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]